Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 16871
Country/Region: Nigeria
Year: 2014
Main Partner: Institute of Human Virology, Nigeria
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $35,743,182 Additional Pipeline Funding: N/A

NOTE: The following is taken from summaries released by PEPFAR on the PEPFAR Data Dashboard. They are incomplete summary paragraphs only and do not contain the full mechanism details. When the full narratives are released, we will update the mechanism pages accordingly.

The Institute of Human Virology, Nigeria (IHVN) through its ACTIONPlus Up Project continued to strengthen its “Hub and Spoke” model of care started in year 1 to provide comprehensive and integrated HIV/AIDS prevention, care and treatment services in 1,078 health facilities. In Benue, Nassarawa and FCT (Tier2 states) scale up of care and treatment services will continue with a focus on hot spots and LGA’s with high prevalence while clients seeking services in Delta, Ekiti, Kano, Katsina, Ogun, Ondo, and Osun will be served accordingly. Vulnerable children, In-school and Out-of- school youth, pregnant women, partners and family members of index clients and key populations will be prioritized in the tier 2 states.

IHVN will support adequate laboratory infrastructure network to facilitate rapid achievement of the goals of PEPFAR/Government of Nigeria (GoN) Partnership Framework, which includes prevention of new infections, improving care and treatment, improving the quality of life of PLHIV and transitioning to host government ownership.

Data for sustainable and evidence-based quality improvement efforts is captured and reported through a system that also continues to strengthen M&E processes across all the facilities and States covered by IHVN with an expansion of the Open MRS Electronic Medical Record (EMR) System in eligible comprehensive sites, while reporting of aggregate program data through DHIS National reporting platform will be strengthened.

PEPFAR-guided rationalization of States to Implementing Partners (IPs) has improved cost-efficiency. IHVN will build on this to enhance the capacity of sub-national levels of government towards improving coverage and quality of HIV/AIDS services to engender ownership and sustainability.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $4,147,244
Care: Orphans and Vulnerable Children (HKID) $2,352,166
Care: TB/HIV (HVTB) $1,368,322
Care: Pediatric Care and Support (PDCS) $314,580
Laboratory Infrastructure (HLAB) $4,379,417
Strategic Information (HVSI) $405,000
Biomedical Prevention: Blood Safety (HMBL) $41,483
Biomedical Prevention: Injection Safety (HMIN) $117,652
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $1,865,634
Sexual Prevention: Other Sexual Prevention (HVOP) $3,947,208
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $3,910,745
Treatment: Adult Treatment (HTXS) $11,974,319
Treatment: Pediatric Treatment (PDTX) $919,412
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
BS_COLL By: Number of whole blood donations screened for HIV in an NBTS ne2rk laboratory 2015 191,700
BS_COLL By: Number of whole blood donations screened for HIV in an NBTS ne2rk laboratory that are identified as reactive for HIV 2015 4,260
BS_COLL Number of whole blood collections each year by the NBTS ne2rk 2015 213,000
GEND_GBV Age: 0-9 2015 42
GEND_GBV Age: 10-14 2015 86
GEND_GBV Age: 15-17 2015 127
GEND_GBV Age: 18-24 2015 75
GEND_GBV Age: 25+ 2015 37
GEND_GBV By PEP service provision (related to sexual violence services provided) 2015 285
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2015 82
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2015 285
GEND_GBV Number of people receiving post-GBV care 2015 367
GEND_GBV Sex: Female 2015 245
GEND_GBV Sex: Male 2015 122
GEND_GBV Sum of Age disaggregates 2015 367
GEND_GBV Sum of Sex disaggregates 2015 367
HTS_TST Age/sex: <1 Female 2015 5,852
HTS_TST Age/sex: <1 Female 2015 5,852
HTS_TST Age/sex: <1 Male 2015 5,622
HTS_TST Age/sex: <1 Male 2015 5,622
HTS_TST Age/sex: 1-4 Female 2015 3,570
HTS_TST Age/sex: 1-4 Female 2015 3,570
HTS_TST Age/sex: 1-4 Male 2015 3,408
HTS_TST Age/sex: 1-4 Male 2015 3,407
HTS_TST Age/sex: 10-14 Female 2015 3,165
HTS_TST Age/sex: 10-14 Female 2015 3,165
HTS_TST Age/sex: 10-14 Male 2015 3,083
HTS_TST Age/sex: 10-14 Male 2015 3,083
HTS_TST Age/sex: 15-19 Female 2015 75,689
HTS_TST Age/sex: 15-19 Female 2015 75,689
HTS_TST Age/sex: 15-19 Male 2015 34,201
HTS_TST Age/sex: 15-19 Male 2015 34,201
HTS_TST Age/sex: 20-24 Female 2015 213,914
HTS_TST Age/sex: 20-24 Female 2015 213,914
HTS_TST Age/sex: 20-24 Male 2015 70,795
HTS_TST Age/sex: 20-24 Male 2015 70,795
HTS_TST Age/sex: 25-49 Female 2015 451,787
HTS_TST Age/sex: 25-49 Female 2015 451,786
HTS_TST Age/sex: 25-49 Male 2015 222,405
HTS_TST Age/sex: 25-49 Male 2015 222,405
HTS_TST Age/sex: 5-9 Female 2015 1,420
HTS_TST Age/sex: 5-9 Female 2015 1,420
HTS_TST Age/sex: 5-9 Male 2015 1,379
HTS_TST Age/sex: 5-9 Male 2015 1,379
HTS_TST Age/sex: 50+ Female 2015 7,100
HTS_TST Age/sex: 50+ Female 2015 7,100
HTS_TST Age/sex: 50+ Male 2015 6,897
HTS_TST Age/sex: 50+ Male 2015 6,897
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 14,006
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 13,493
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 748,490
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 334,297
HTS_TST Aggregated Age/sex: <15 Female 2015 14,006
HTS_TST Aggregated Age/sex: <15 Male 2015 13,493
HTS_TST Aggregated Age/sex: 15+ Female 2015 748,490
HTS_TST Aggregated Age/sex: 15+ Male 2015 334,297
HTS_TST By Test Result: Negative 2015 1,081,777
HTS_TST By Test Result: Negative 2015 1,081,777
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 1,110,286
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 1,110,286
HTS_TST Sum of Age/Sex disaggregates 2015 1,110,286
HTS_TST Sum of Age/Sex disaggregates 2015 1,110,286
HTS_TST Sum of Aggregated Age/Sex <15 2015 27,499
HTS_TST Sum of Aggregated Age/Sex <15 2015 27,499
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 1,082,787
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 1,082,787
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 1,110,286
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 1,110,286
HTS_TST Sum of Test Result disaggregates 2015 1,110,286
HTS_TST Sum of Test Result disaggregates 2015 1,110,286
HTS_TST_POS By Test Result: Positive 2015 28,509
HTS_TST_POS By Test Result: Positive 2015 28,509
LAB_ACC By site support type: Direct Service Delivery (DSD) 2015 10
LAB_ACC Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation 2015 10
LAB_ACC Sum of Support Type disaggregates 2015 10
LAB_CAP By clinical laboratories 2015 94
LAB_CAP By site support type: Direct Service Delivery (DSD) 2015 94
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2015 94
LAB_CAP Sum of Site Support Type disaggregates 2015 94
OVC_ACC Age: <1 2015 1,460
OVC_ACC Age: 1-4 2015 6,083
OVC_ACC Age: 10-14 2015 5,840
OVC_ACC Age: 15-17 2015 3,407
OVC_ACC Age: 18+ 2015 730
OVC_ACC Age: 5-9 2015 6,813
OVC_ACC Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services 2015 24,333
OVC_ACC Sex: Female 2015 12,410
OVC_ACC Sex: Male 2015 11,923
OVC_ACC Sum of Age disaggregates 2015 24,333
OVC_ACC Sum of Sex disaggregates 2015 24,333
OVC_SERV Age: <1 2015 4,867
OVC_SERV Age: 1-4 2015 20,277
OVC_SERV Age: 10-14 2015 19,466
OVC_SERV Age: 15-17 2015 11,355
OVC_SERV Age: 18+ 2015 2,433
OVC_SERV Age: 5-9 2015 22,711
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2015 81,109
OVC_SERV Sex: Female 2015 41,366
OVC_SERV Sex: Male 2015 39,743
OVC_SERV Sum of Age disaggregates 2015 81,109
OVC_SERV Sum of Sex disaggregates 2015 81,109
PMTCT_ARV Life-long ART (including Option B+) 2015 6,311
PMTCT_ARV Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2015 573
PMTCT_ARV Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) 2015 4,590
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 12,609
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 11,474
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 4,172
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 2,138
PMTCT_ARV Sum of New and Current disaggregates 2015 6,310
PMTCT_ARV Sum of Regimen Type disaggregates 2015 11,474
PMTCT_ARV_NGI Life-long ART (including Option B+) 2015 6,311
PMTCT_ARV_NGI Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2015 573
PMTCT_ARV_NGI Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) 2015 4,590
PMTCT_ARV_NGI Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 12,609
PMTCT_ARV_NGI Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 11,474
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 4,172
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 2,138
PMTCT_ARV_NGI Sum of New and Current disaggregates 2015 6,310
PMTCT_ARV_NGI Sum of Regimen disaggregates 2015 11,474
PMTCT_EID By infants who received a virologic test within 2 months of birth 2015 3,786
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2015 7,688
PMTCT_EID By infants with a positive virologic test result within 12 months of birth 2015 574
PMTCT_EID Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) 2015 13,284
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2015 11,474
PMTCT_EID Sum of Infant Age disaggregates 2015 11,474
PMTCT_STAT By: Known positives at entry 2015 5,044
PMTCT_STAT By: Number of new positives identified 2015 7,565
PMTCT_STAT Number of new ANC and L&D clients 2015 445,854
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 405,727
PMTCT_STAT Sum of Positives Status disaggregates 2015 12,609
PMTCT_STAT_NGI By: Known positives at entry 2015 5,044
PMTCT_STAT_NGI By: Number of new positives identified 2015 7,565
PMTCT_STAT_NGI Number of new ANC and L&D clients 2015 445,854
PMTCT_STAT_NGI Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 405,727
PMTCT_STAT_NGI Sum of Positives Status disaggregates 2015 12,609
PP_PREV Age/sex: 10-14 Female 2015 2,927
PP_PREV Age/sex: 10-14 Male 2015 2,812
PP_PREV Age/sex: 15-19 Female 2015 3,512
PP_PREV Age/sex: 15-19 Male 2015 3,374
PP_PREV Age/sex: 20-24 Female 2015 8,781
PP_PREV Age/sex: 20-24 Male 2015 8,436
PP_PREV Age/sex: 25-49 Female 2015 13,171
PP_PREV Age/sex: 25-49 Male 2015 12,655
PP_PREV Age/sex: 50+ Female 2015 878
PP_PREV Age/sex: 50+ Male 2015 844
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2015 57,390
PP_PREV Sum of Age/Sex disaggregates 2015 57,390
PP_PREV Total number of people in the target population 2015 208,503
QI_SITE By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months 2015 156
QI_SITE By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC 2015 204
QI_SITE Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months 2015 156
QI_SITE Sum of Numerator Site Support Type disaggregates 2015 156
QI_SITE Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC 2015 204
QI_SITE_den Sum of Denominator Site Support Type disaggregates 2015 204
TB_ART Age: 0-4 2015 48
TB_ART Age: 15+ 2015 4,506
TB_ART Age: 5-14 2015 240
TB_ART Aggregated Age: <15 2015 288
TB_ART Aggregated Age: 15+ 2015 4,506
TB_ART Female 2015 2,445
TB_ART Known HIV-positive 2015 2,061
TB_ART Male 2015 2,349
TB_ART Newly tested 2015 2,733
TB_ART Sum of Aggregated Age disaggregates 2015 4,794
TB_ART Sum of Sex disaggregates 2015 4,794
TB_ART Sum of Test Status disaggregates 2015 4,794
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2015 4,794
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2015 4,794
TB_SCREEN Age: <1 2015 2,841
TB_SCREEN Age: 1-4 2015 1,420
TB_SCREEN Age: 10-14 2015 1,420
TB_SCREEN Age: 15-19 2015 14,204
TB_SCREEN Age: 20-24 2015 35,509
TB_SCREEN Age: 25-49 2015 78,120
TB_SCREEN Age: 5-9 2015 2,841
TB_SCREEN Age: 50+ 2015 5,681
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 2015 8,522
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ 2015 133,514
TB_SCREEN Sex: Female 2015 99,425
TB_SCREEN Sex: Male 2015 42,611
TB_SCREEN Sum of Age disaggregates 2015 22,726
TB_SCREEN Sum of Aggregated Age disaggregates 2015 142,036
TB_SCREEN Sum of Sex disaggregates 2015 142,036
TB_SCREEN The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2015 142,036
TX_CURR Age/Sex: <1 Female 2015 181
TX_CURR Age/Sex: <1 Male 2015 204
TX_CURR Age/Sex: 1-4 Female 2015 851
TX_CURR Age/Sex: 1-4 Male 2015 960
TX_CURR Age/Sex: 15+ Female 2015 65,315
TX_CURR Age/Sex: 15+ Male 2015 32,171
TX_CURR Age/Sex: 5-14 Female 2015 1,548
TX_CURR Age/Sex: 5-14 Male 2015 1,746
TX_CURR Aggregated Age/Sex: <1 Female 2015 181
TX_CURR Aggregated Age/Sex: <1 Male 2015 204
TX_CURR Aggregated Age/Sex: <15 Female 2015 2,580
TX_CURR Aggregated Age/Sex: <15 Male 2015 2,909
TX_CURR Aggregated Age/Sex: 15+ Female 2015 65,316
TX_CURR Aggregated Age/Sex: 15+ Male 2015 32,171
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2015 102,976
TX_CURR Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] 2015 5
TX_CURR Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] 2015 66
TX_CURR Sum of age/sex disaggregates 2015 5,490
TX_CURR Sum of Aggregated Age/Sex <15 2015 5,489
TX_CURR Sum of Aggregated Age/Sex 15+ 2015 97,487
TX_CURR Sum of Aggregated Age/Sex disaggregates 2015 102,976
TX_CURR_NGI Age/Sex: <1 Female 2015 181
TX_CURR_NGI Age/Sex: <1 Male 2015 204
TX_CURR_NGI Age/Sex: 1-4 Female 2015 851
TX_CURR_NGI Age/Sex: 1-4 Male 2015 960
TX_CURR_NGI Age/Sex: 15+ Female 2015 65,316
TX_CURR_NGI Age/Sex: 15+ Male 2015 32,171
TX_CURR_NGI Age/Sex: 5-14 Female 2015 1,546
TX_CURR_NGI Age/Sex: 5-14 Male 2015 1,746
TX_CURR_NGI Aggregated Age/Sex: <1 Female 2015 181
TX_CURR_NGI Aggregated Age/Sex: <1 Male 2015 204
TX_CURR_NGI Aggregated Age/Sex: <15 Female 2015 2,580
TX_CURR_NGI Aggregated Age/Sex: <15 Male 2015 2,909
TX_CURR_NGI Aggregated Age/Sex: 15+ Female 2015 65,316
TX_CURR_NGI Aggregated Age/Sex: 15+ Male 2015 32,170
TX_CURR_NGI Number of adults and children receiving antiretroviral therapy (ART) 2015 102,975
TX_CURR_NGI Sum of Age/Sex disaggregates 2015 102,975
TX_CURR_NGI Sum of Aggregated Age/Sex <15 2015 5,489
TX_CURR_NGI Sum of Aggregated Age/Sex 15+ 2015 97,486
TX_CURR_NGI Sum of Aggregated Age/Sex disaggregates 2015 102,975
TX_NEW Aggregated Grouping by Age: <1 Male 2015 222
TX_NEW Aggregated Grouping by Age/Sex: <1 Female 2015 518
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2015 1,185
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2015 508
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2015 21,050
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2015 9,022
TX_NEW Breastfeeding status 2015 1,053
TX_NEW By Age/Sex: <1 Female 2015 518
TX_NEW By Age/Sex: <1 Male 2015 222
TX_NEW By Age/Sex: 1-4 Female 2015 378
TX_NEW By Age/Sex: 1-4 Male 2015 162
TX_NEW By Age/Sex: 10-14 Female 2015 111
TX_NEW By Age/Sex: 10-14 Male 2015 48
TX_NEW By Age/Sex: 15-19 Female 2015 2,224
TX_NEW By Age/Sex: 15-19 Male 2015 953
TX_NEW By Age/Sex: 20-24 Female 2015 3,335
TX_NEW By Age/Sex: 20-24 Male 2015 1,429
TX_NEW By Age/Sex: 25-49 Female 2015 14,454
TX_NEW By Age/Sex: 25-49 Male 2015 6,194
TX_NEW By Age/Sex: 5-9 Female 2015 178
TX_NEW By Age/Sex: 5-9 Male 2015 76
TX_NEW By Age/Sex: 50+ Female 2015 1,038
TX_NEW By Age/Sex: 50+ Male 2015 445
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2015 31,765
TX_NEW Pregnancy status 2015 2,105
TX_NEW Sum of Age/Sex disaggregates 2015 31,765
TX_NEW Sum of Aggregated Age/Sex disaggregates 2015 31,765
TX_RET Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 549
TX_RET Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 26,061
TX_RET Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 823
TX_RET Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 1,372
TX_RET Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 26,061
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2015 27,433
TX_RET Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 12,893
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2015 32,274
TX_RET_den Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 645
TX_RET_den Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 30,660
TX_RET_den Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 968
TX_RET_den Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 1,614
TX_RET_den Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 30,660
TX_RET_den Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 1,517
Cross Cutting Budget Categories and Known Amounts Total: $2,184,454
Renovation $305,000
Gender: Gender Equality $234,865
Promoting gender-related policies and laws that increase legal protection
Capacity building
Equity in HIV prevention, care, treatment and support
Monitoring and Evaluation
Gender: Gender Based Violence (GBV) $117,432
GBV Prevention
Capacity building
Post GBV Care
Monitoring and Evaluation
Condoms: Policy, Tools, and Services $1,527,157
Key Issues Identified in Mechanism
enumerations.Malaria (PMI)
Child Survival Activities
Mobile Populations
Safe Motherhood
Tuberculosis
End-of-Program Evaluation
Family Planning